Cognition Therapeutics aligns with FDA on Phase III DLB trial and reports Q3 loss decline
Cognition Therapeutics said its work with the FDA resulted in agreement on primary and key secondary endpoints for a registrational Phase III study of zervimesine in dementia with Lewy bodies. The company posted a Q3 2026 net loss of $4.14 million, or $0.04 per share, and held $31.5 million in cash and equivalents, which it expects to fund operations through Q4 2027. It also noted that top‑line results from its Phase II START Alzheimer’s trial are expected in the second half of 2027.
Why it matters
The FDA alignment reduces regulatory uncertainty for the upcoming Phase III trial, potentially de‑risking the program for investors. The cash runway into Q4 2027 gives the company sufficient liquidity to advance the trial and fund ongoing operations, according to the press release.
Key facts
- 1Cognition aligned with the FDA on primary and key secondary endpoints for a Phase III registrational study of zervimesine in dementia with Lewy bodies. stocktitan.net
- 2Cash, cash equivalents and restricted cash totaled $31.5 million as of September 30, 2026. rttnews.com
- 3Net loss for the quarter ended September 30, 2026 was $4.14 million, or $0.04 per share. rttnews.com
- 4Grant income for the quarter was $2.97 million, up from $1.21 million a year earlier. rttnews.com
- 5Top‑line results from the Phase II START Alzheimer’s trial are anticipated in the second half of 2027. stocktitan.net
- 6The Phase III trial will use the NPI‑2 psychosis measure as its primary endpoint. finance.yahoo.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.